ROS1 fusion is a rare but important driver mutation in NSCLC, which usually shows significant sensitivity to small molecule tyrosine kinase inhibitors (TKIs), such as crizotinib, alectinib, entrutinib, ceritinib, lorlatinib, and brigatinib.[4] Since the various fusion variants may have an effect on therapeutic efficacy, accurate detection of ROS1 rearrangements is critical. This evidence concerns the gene ROS1 and non-small cell lung carcinoma.